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Background: There is a lack of high quality evidence concerning the efficacy of total knee arthroplasty (TKA).
According to international evidence-based guidelines, treatment of knee osteoarthritis (KOA) should include patient
education, exercise and weight loss. Insoles and pharmacological treatment can be included as supplementary
treatments. If the combination of these non-surgical treatment modalities is ineffective, TKA may be indicated. The
purpose of this randomised controlled trial is to examine whether TKA provides further improvement in pain,
function and quality of life in addition to optimised non-surgical treatment in patients with KOA defined as definite
radiographic OA and up to moderate pain.
Methods/Design: The study will be conducted in The North Denmark Region. 100 participants with radiographic
KOA (K-L grade ≥2) and mean pain during the previous week of≤ 60 mm (0–100, best to worst scale) who are
considered eligible for TKA by an orthopaedic surgeon will be included. The treatment will consist of 12 weeks of
optimised non-surgical treatment consisting of patient education, exercise, diet, insoles, analgesics and/or NSAIDs.
Patients will be randomised to either receiving or not receiving a TKA in addition to the optimised non-surgical
treatment. The primary outcome will be the change from baseline to 12 months on the Knee Injury and
Osteoarthritis Outcome Score (KOOS)4 defined as the average score for the subscale scores for pain, symptoms,
activities of daily living, and quality of life. Secondary outcomes include the five individual KOOS subscale scores,
EQ-5D, pain on a 100 mm Visual Analogue Scale, self-efficacy, pain pressure thresholds, and isometric knee flexion
and knee extension strength.
Discussion: This is the first randomised controlled trial to investigate the efficacy of TKA as an adjunct treatment to
optimised non-surgical treatment in patients with KOA. The results will significantly contribute to evidence-based
recommendations for the treatment of patients with KOA.
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Indications for total joint arthroplasty (TJA) vary greatly
among countries [1]. Although patients considered eligible
for TJA on average report more pain and functional limita-
tion than patients not eligible for TJA, the overlap is
substantial and no cut-offs can be established [2]. Adding a
radiographic score to patient-reported pain and function
does not improve identification of those considered eligible
for TJA [2]. The incidence of total knee arthroplasty (TKA)
in younger patients has rapidly increased [3,4] and only
about every second patient considered eligible for TKA
reported pain of about 50 or worse on a 0 to 100 scale [2],
suggesting a broadening of indications to include also
younger patients with less severe symptoms. A consensus
on the indication for TKA in knee osteoarthritis (KOA) is
in high demand, but requires the development of high qual-
ity evidence for the treatment options in KOA.
Evidence suggests that treatment of KOA should include
multiple parallel treatment modalities [5,6]. On the basis of
the existing evidence, clinical guidelines recommend a com-
bination of patient education, exercise and weight loss as
the first treatment option and that insoles and pharmaco-
logical treatment can be included as supplements [5-7].
Strong evidence suggests that exercise [8-11] and weight
loss [12-14] reduce pain and improve functional level in
patients with KOA. Furthermore, the evidence shows that
patients with KOA undergoing patient education experi-
ence reduced pain and functional disability and improved
wellbeing [10,15,16], while the evidence concerning insoles
is conflicting, but still recommended [6,17,18]. Acetamino-
phen (paracetamol) reduces pain in KOA [19,20], and it is
recommended as the analgesic of first choice [5-7]. When
pain is insufficiently controlled with paracetamol, the
addition of a second analgesic such as short term NSAID is
recommended [5,6].
When non-surgical treatment is ineffective, TKA may be
indicated [5-7]. The existing studies report improvement in
pain and function following TKA [21]. However the quality
of the evidence can be questioned since no RCTs have
evaluated the efficacy of TKA compared with other treat-
ment modalities [6]. Around 20 % of patients who receive a
TKA experience little or no improvement in pain, disability
and/or quality of life; a substantial proportion even develops
chronic pain following TKA [22,23]. Hence, there is a need
to further improve the treatment algorithm for KOA.
Optimisation of treatment may be done by combining
the recommended non-surgical treatment modalities as a
previous RCT suggests there may be an additive effect
[13]. However, no one has yet investigated the combined
effect of all the recommended non-surgical treatment
modalities or the effect of an optimised non-surgical
treatment combined with a TKA.
The purpose of this study is to examine whether TKA
provides further improvement in quality of life, pain andfunction in addition to a 12-week evidence-based non-
surgical treatment program in patients referred from pri-
mary care to an orthopaedic surgeon for evaluation of
the need for TKA, with definite radiographic OA and no
more than moderate pain.
We hypothesise that TKA, in addition to optimised
non-surgical treatment, results in a significantly greater
pain reduction, functional improvement and increase in
quality of life at the 12-month follow-up in patients con-
sidered in need of TKA, with definite radiographic OA
and a mean VAS pain score during the previous week of
60 or less.
Methods/Design
Study design
This is a randomised, assessor-blinded, controlled trial of
TKA in addition to a 12-week multimodal, systematic non-
surgical treatment (the MEDIC-treatment) with 12-month
follow-up. Measurements will be taken at baseline, and 12,
26 and 52 weeks after the start of the MEDIC-treatment.
The protocol conforms to CONSORTguidelines for parallel
group randomised trials [24] and the protocol is designed
to conform to the principles of the Declaration of Helsinki
and has been approved by the local Ethics Committee of
The North Denmark Region (N-20110024).
Participants
The inclusion and exclusion criteria is selected to include
patients considered to have a relative indication for
TKA. This indication is defined as a knee condition con-
sidered by an orthopaedic surgeon to be in need of TKA,
having definite radiographic KOA and having a mean
Visual Analogue Scale (VAS) pain score during the pre-
vious week of 60 or less. This is in contrast to those con-
sidered to have an absolute indication for TKA defined
as a report of a mean VAS pain score during the previ-
ous week of 60 or more.
We will recruit 100 patients meeting the following in-
clusion criteria:
1. Referred from primary care to an orthopaedic
surgeon in a public hospital in The North Denmark
Region for evaluation of the need for TKA;
2. Considered eligible for TKA by the surgeon;
3. Diagnosed with KOA using standing, weight-bearing
knee radiographs (Kellgren-Lawrence score ≥2 on
the original scale [25,26]); and
4. Aged ≥18 years.
The exclusion criteria are:
1. Bilateral simultaneous TKA;
2. Revision of prior TKA, unicompartmental knee
arthroplasty or high tibial osteotomy;
3. Rheumatoid arthritis;
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VAS;
5. Possible pregnancy or planning pregnancy;
6. Inability to comply with the protocol; and
7. Inadequacy in written and spoken Danish.
Procedure
The overall structure of the study is outlined in Figure 1.
People in need of evaluation for TKA in The North
Denmark Region are referred by their general practitioner
to the outpatient clinics at Frederikshavn and Farsoe,
Department of Orthopaedic Surgery, Aalborg Hospital,
which specialise in performing TKA. A standardised
weight-bearing antero-posterior knee x-ray is obtained [27].
In addition to written and verbal information, potential
participants will watch a DVD as part of the recruitment
process to standardise the information concerning the
project. The DVD provides a description of the project
in lay language and evidence-based information on what
currently is known about KOA.
One of the orthopaedic surgeons at the outpatient
clinics will assess potential participants against the inclu-
sion criteria and exclusion criteria 1–3 and a researchParticipants allocated 
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Figure 1 Flowchart.health worker assigned to the project will assess them
against exclusion criteria 4–7. Informed written consent
will be obtained from patients who are eligible and willing
to participate. After the baseline measures are obtained,
patients who agree to participate in the randomised con-
trolled trial will receive their treatment assignment, either
(i) TKA in addition to the MEDIC-treatment or (ii) the
MEDIC-treatment only.
Participants will be reassessed after 12-weeks of MEDIC-
treatment (12 week follow-up) and again after 6 months
(26 weeks) and 12 months (52 weeks). In addition, there will
be long-term follow-ups at two, five and ten years. Partici-
pants are asked to refrain from other treatments during the
trial. All current medication use, co-morbidities and co-
interventions will be recorded at all follow-ups.
Randomisation procedure and concealment of allocation
The schedule for randomisation will be randomly generated
using a computer before the initiation of the trial. The ran-
domisation will be by random permuted blocks, stratified
according to the clinic (Frederikshavn or Farsoe) to control
for variation in patient characteristics in the two clinics. To
conceal the outcomes of the randomisation, the allocationParticipants choosing 
TKA in addition to 
MEDIC-treatment 
 orthopaedic surgeon for 
e North Denmark Region 
Patients not meeting all of the 
inclusion criteria or meeting one or 
more of the exclusion criteria 
eeks after the start of the MEDIC-treatment
e: KOOS4
t: 52 weeks 
Participants choosing 
MEDIC-treatment 
 protocol (as treated) 
sis
-Up
patients 
 to participate 
Observational Cohort
Skou et al. BMC Musculoskeletal Disorders 2012, 13:67 Page 4 of 11
http://www.biomedcentral.com/1471-2474/13/67numbers will be put in concealed, opaque C5 envelopes. In
blocks of eight, these envelopes will be placed in consecu-
tively numbered opaque larger envelopes (seven larger
envelopes in total for each clinic). An independent staff
member will prepare the envelopes. These will be kept in a
locked location accessible only by one research assistant at
each of the respective clinics. Following the informed con-
sent and completion of the baseline measures, a smaller en-
velope from the numbered larger envelopes will be opened
by the research assistant and the allocation revealed to the
participant. When only two smaller envelopes are left in the
first of the numbered larger envelopes, the smaller envel-
opes of the second larger envelope will be added. When
there are six smaller envelopes left in the sixth of the num-
bered larger envelopes at each clinic, the last two of the
smaller envelopes will be added.Blinding
The outcome assessor will be blinded to group alloca-
tion, will not be involved in providing the interventions,
and will be unaffiliated with the treatment sites. The par-
ticipants and the project physiotherapist delivering part
of the interventions cannot be blinded. The statistician
performing the statistical analyses will be blinded to
group allocation.The observational cohort study
Patients refusing to participate in the randomised con-
trolled trial will be offered the option of participating in
an observational cohort. The inclusion and exclusion cri-
teria, study intervention, follow-up schedule, and study
endpoints will be identical to the randomised controlled
trial. The only difference is that the treatment will not be
randomly assigned, because the participants will be able
to choose between (i) TKA in addition to the MEDIC-
treatment or (ii) the MEDIC-treatment.
Patients refusing to participate in both the randomised
controlled trial and the observational cohort will be
asked to fill out the Knee Injury and Osteoarthritis
Outcome Score (KOOS) and report age and gender an-
onymously so as to improve the failure analysis.Interventions
Total knee arthroplasty
Surgery will be performed within 8 weeks from inclusion in
the trial for all patients receiving a TKA in addition to the
MEDIC-treatment. The surgery will be performed by the
orthopaedic surgeon who assessed them during the recruit-
ment phase at one of the two clinics.
A total cemented prosthesis with patellar resurfacing
(NexGen CR-Flex fixed or LPS-Flex fixed, Zimmer,
Warsaw, Indiana, USA) will be applied using standard
methods [28].Participants will be mobilised to sitting or standing
within a few hours after surgery. Active and passive
flexion and extension exercises following a standard
protocol of The North Denmark Region will be initiated
the day after surgery by a physiotherapist and continued
once or twice daily during the hospitalisation phase, nor-
mally 2–3 days, to improve range of movement and
muscle strength. After discharge, this treatment will be
continued concurrently with the MEDIC-treatment
supervised by the project physiotherapist.
The MEDIC-treatment
The MEDIC-treatment consists of five different interven-
tions. Following the clinical guidelines, patient education,
exercise and weight loss are the three core elements,
while insoles and pharmacological treatment will be
included when meeting objective test criteria and if con-
sidered needed by the treating clinician [5-7].
The participants allocated to, or choosing, TKA in
addition to the MEDIC-treatment will start the MEDIC-
treatment immediately after discharge from the hospital fol-
lowing their TKA (anticipated mean hospitalisation stay
3–4 days). The participants allocated to, or choosing, the
MEDIC-treatment only will start the intervention right
away. The MEDIC-treatment will take place at one site
(Aalborg), located geographically between Frederikshavn
and Farsoe.
Patient education
The purpose of the patient education in this study is to
encourage the participant to actively engage in and take
responsibility for the management and treatment of their
KOA. The patient education is based on principles from
The Osteoarthritis Management Course developed in
Sweden (BOA, Gothenburg, Sweden), and consists of
two sessions with a duration of 60 minutes each. The
first session will focus on the diagnosis of KOA, the
aetiology, symptoms and risk factors and a short over-
view will be given on the current treatment options of
KOA. In the second session an in-depth description will
be given of how KOA can be treated as well as guidance
in self-help tools in relation to KOA. Both sessions will
be held by the project physiotherapist in groups of up to
16 participants. The physiotherapist will facilitate discus-
sion and interaction between the participants. Further-
more, the participants will receive a DVD containing all
information that was provided during patient education.Exercise
The NEuroMuscular EXercise training program for
patients with osteoarthritis of the knee or hip who are
scheduled for total joint replacement (NEMEX-TJR) will
be applied in this study. It is a training program based
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in patients with severe hip or knee OA [29].
The duration of an exercise session is 60 min. and will be
completed 2 times a week in the 12-week intervention
period. The focus is on the affected leg, but exercises are
carried out with both legs. The project physiotherapist
heading the exercise is a specialist in the area and has parti-
cipated in a course in NEMEX-TJR held by the originators.
The participants will be under the supervision and instruc-
tion of the project physiotherapist and the training will also
be supplied as images and text. The training will be class-
based at Aalborg University Hospital (in classes of up to 8
participants). After 12 weeks of training it will shift to being
home-based individual training, as the combination of
class-based and individual home-based training has been
shown to reduce pain more than home-based exercise alone
[30]. Participants will be admitted continuously into the
class so that the class consists of both novices as well as
experienced participants. Each participant will be monitored
individually to ensure that the training is tailored to the
individual’s level of function and pain.
Pain is a significant problem for patients with KOA
[31]. For that reason, the participants will be asked to
monitor their pain during training in collaboration with
the project physiotherapist using a VAS-scale. Pain up to
5 is “acceptable” during and after the exercise session.
The morning after an exercise session, pain should sub-
side to “pain as usual”. If pain does not subside, the in-
tensity of the training will be reduced [32]. This pain
monitoring system is part of the NEMEX program.
Diet
Participants with a Body Mass Index (BMI) ≥25 at
baseline will be referred to a 12-week dietary weight
loss program. The goal of the intervention is a re-
duction in body weight by at least 5 % and retention
of this throughout the project period. The 5 % re-
duction in body weight is required to experience
symptomatic relief [14]. The dietary intervention is
carried out by the project dietician and is based on
principles from Motivational Interviewing (MI) and
consists of instruction and guidance in relation to
diet. The participant’s readiness to change will be
evaluated and forms the basis of the intervention.
The focus is on getting the participant to take action
regarding their diet using different strategies [33].
These strategies are supported by diet plans, written
guides, recipes etc. depending on the needs of the
individual participant. All participants referred to the
project dietician will have four dietary sessions. The
first session will take place in the first week of the
intervention (60 minutes), while session 2–4 will take
place 3, 6 and 11 weeks after the start of the inter-
vention (30 minutes).Insoles
The participants will receive one of two possible insoles
depending on their hip-knee-foot alignment. The project
physiotherapist will assess knee alignment using the sin-
gle limb mini squat. The single limb mini squat has been
found to be a valid and reliable tool when investigating
medio-lateral motion of the knee in clinical settings [34].
Participants will be scored as having either a knee-
medial-to-foot position (the knee moves medially to the
2nd toe in three or more of five trials), a knee-above-foot
position (the knee moves between the 2nd and the 5th
toe) or a knee-lateral-to-foot position (the knee moves
over or lateral to the 5th toe).
1. Participants who score a knee-medial-to-foot or a
knee-above-foot position will get an individually
fitted non-wedged full length Formthotics System
insole with medial arch support (Foot Science
International, Christchurch, New Zealand).
2. Participants who score a knee-lateral-to-foot position
will get an individually fitted 4 ° laterally wedged full
length Formthotics System insole with medial arch
support (Foot Science International, Christchurch,
New Zealand).
The participants will be requested to use the insoles
bilaterally in all shoes every day.
Medicine
In the case of no contraindications, paracetamol 1 g
four times daily, ibuprofen 400 mg three times daily,
and pantoprazol 20 mg daily will be prescribed for
use during the intervention period. The prescription
will be renewed every three weeks in order to
supervise the use of, and indications for, medication.
If the patient experiences pain relief, making them
question continuation of the prescription during a
three-week period, they will be urged to contact the
research physiotherapist who will record the discon-
tinuation of medication.
Booster sessions after the 12 weeks of MEDIC-treatment
Following the 12-week MEDIC-treatment, the partici-
pants will be encouraged to continue the MEDIC-
treatment unsupervised at home with the same fre-
quency as during the 12-week intervention. There will
be a transition period of 8 weeks where the participants
will exercise in class and at home alternately, and two
additional 30-minute telephone sessions with the project
dietician (26 and 39 weeks after the start of the MEDIC-
treatment) will be scheduled. Furthermore, the partici-
pants will be contacted by telephone by the project
physiotherapist 8 times in the interval between the tran-
sition period and the 12-month follow-up to ensure a
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initiatives have previously been found to be effective,
even in relation to long-term outcomes [13,35,36].
Crossovers
Crossovers are a common problem in studies randomising
to operative or non-operative treatment [37,38]. To
minimize the number of crossovers, the following initiatives
are used: Participants randomised to both MEDIC-
treatment and TKA will exercise together and those with
MEDIC-treatment only will be in their own class. At the
same time, the project physiotherapist and project dietician
will be trained in retention of the participants in their
respective groups based on experience from previous
studies [13,35,39-45].
Participants who experience impairment of their symp-
toms will be reassessed by the orthopaedic surgeon who
assessed them in the recruitment phase. Pre-defined criteria
for crossover to TKA or revision of TKA are a score for
quality of life and/or for pain equal to or below 25 on the
KOOS and agreement between the participant and the
orthopaedic surgeon that a TKA or revision of a TKA is
necessary.
The reason for each crossover will be registered. Partici-
pants crossing over will remain in the study and analysed in
a intention-to-treat analyses.
Baseline data
Gender, age, nationality, height, alcohol intake, smoking
habits, duration of KOA symptoms, previous injuries, treat-
ment and use of medication regarding the affected knee,
co-morbidities, physical activity and exercise, preferred
treatment, previous arthroplasty, living arrangement, satis-
faction with self-management of pain, education level and
employment status, income, home help, and the short ver-
sion of the Hip/Knee Osteoarthritis Decision Quality In-
strument (HK-DQI)[46] will be obtained by questionnaire.
After the randomisation, the participant will be asked about
their belief in the effect of the assigned/chosen treatment
in relation to pain, function and quality of life. The radio-
graphic severity of KOA will be assessed on the baseline x-
ray using the Kellgren and Lawrence grading system [25].
Primary outcome measure
The primary outcome will be the change from baseline to
12 months in the average score for four of the five Knee
Injury and Osteoarthritis Outcome Score subscales covering
pain, symptoms, activities of daily living, and quality of life
(KOOS4), with scores ranging from 0 (worst) to 100 (best)
(Table 1) [47,48].
Secondary outcome measures
Several other patient-reported outcome measures will
be used (Table 1). The five subscales of KOOS (the fifthscale being difficulty in sports and recreational activ-
ities) [47,48], the EQ-5D-3L for economic appraisal
[49], and self-efficacy in relation to reducing pain and
increasing function and quality of life using a 100 mm
VAS with terminal descriptors of ‘very unsure’ and ‘very
sure’ will be used. Furthermore, pain intensity will be
measured on a 100 mm VAS with terminal descriptors
of ‘no pain’ and ‘worst pain possible’ in the following
situations: at rest, after 30 min. of walking and worst
pain and least pain in the previous 24 hours. The parti-
cipants will be asked to shade regions where they have
had pain during the previous 24 hours on a region-
divided body chart.
A number of objective measures will be assessed
(Table 1). Prior to the start of the study, the outcome
assessor will undergo a period of supervised training in
how to use the objective measures to optimise the reli-
ability of the measurements. To retain the blinding of
the assessor, all participants will be wearing a loose
sticking plaster on both knees at all follow-ups to cover
the area were a possible scar from the surgery would
be. A Timed Up and Go [50] and 20-meter walk test
[51] will be used as measures of the functional per-
formance of the participants. Percentage change in
weight from baseline to follow-up is another objective
measure which will be used in this study. The partici-
pant’s weight will be measured without shoes at the
same time of day and on the same scale (seca 813, seca
gmbh & co. kg., Hamburg, Germany) at baseline and at
all follow-ups.
Maximum isometric muscle strength will be measured
in knee flexion and knee extension bilaterally in a make
test using a handheld dynamometer (HHD), the Power-
track IITM Commander (JTech Medical Industries, Salt
Lake City, Utah, USA). The participant will be seated on
an examination couch with their hip in a 90 ° flexion pos-
ition and instructed in stabilising themselves by holding
onto both sides of the couch. The HHD will be fastened to
the couch (knee extension) or a wall bar in front of the
participant (knee flexion) with a strap keeping the HHD
just proximal to the lateral malleolus, perpendicular to the
limb being tested, to ensure that the knee is kept in a 75°
angle during the test, a starting position used in previous
studies when measuring isometric strength in KOA
[52,53]. The participant will be asked to carry out a 5-sec-
ond isometric maximum voluntary contraction (MVC)
pushing against the dynamometer and the hand of the
examiner. The assessor will use the standardised cue “push
. . . hold, hold, hold and relax” and encourage the partici-
pant to do their best. To ensure that the participant has
understood the test procedure, he or she will be asked to
perform a sub-maximal test and then an MVC before
starting the measurement. The highest value of four con-
secutive measurements and the mean of the three highest
Table 1 Study measures
Construct assessed Data collection instrument Time of collection
Primary outcome measure
Pain, symptoms, physical function and QOL Average score of four of the KOOS subscales, KOOS4 0, 12, 26 and 52 weeks
Secondary outcome measures Data collection instrument Time of collection
PROMs
Pain, symptoms, ADL, QOL and Sport & Rec The five individual subscales of KOOS 0, 12, 26 and 52 weeks
Health outcome EQ-5D-3 L 0, 12, 26 and 52 weeks
Self-efficacy in improving pain, function and QOL 100 mm VAS 0, 12, 26 and 52 weeks
Pain intensity in various situations 100 mm VAS 0, 12, 26 and 52 weeks
Pain location Region-divided body chart 0, 12, 26 and 52 weeks
Objective measures
Functional performance Timed Up and Go 0, 12, 26 and 52 weeks
Functional performance 20-meter walk test 0, 12, 26 and 52 weeks
Weight change Percentage-wise change in weight from baseline
to follow-up
0, 12, 26 and 52 weeks
Muscle strength HHD - maximum isometric strength
in flexion and extension
0, 12, 26 and 52 weeks
Pain reactions Handheld algometer – PPTs at four sites in the
peripatellar region and at m. tibialis anterior
0, 12, 26 and 52 weeks
Other measures Data collection instrument Time of collection
Compliance with exercise Treatment records, log-book Continuously
Use of medication Questionnaire 0, 12, 26 and 52 weeks
Compliance with diet, insoles and patient education A five-point scale (ranging from never to all the time) 0, 12, 26 and 52 weeks
Satisfaction A five-point Likert scale 0, 12, 26 and 52 weeks
Adverse events Treatment records, hospital records and questionnaire Continuously
Health and non-health care costs Hospital records and questionnaire 0, 12, 26 and 52 weeks
PROMs =Patient-reported outcome measures, QOL =quality of life, ADL = activities of daily living, Sport & Rec = sports and recreational activities, HHD=Handheld
Dynamometer, PPTs = Pressure pain thresholds.
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and knee flexion. The participant will be given a 30-second
rest between each measurement.
To assess pressure pain thresholds (PPTs), a hand-held
pressure algometer (Algometer Type II, Somedic AB,
Hoerby, Sweden) with a 1 cm2 probe will be used. The
probe will be placed perpendicular to the skin and force
applied at a constant rate of 30 kPa/s until the partici-
pant defines the pressure as pain and presses a button.
PPTs will be assessed bilaterally at one control site on
m. tibialis anterior (5) (5 cm distal to the tibial tuberos-
ity) and four sites in relation to bony landmarks in the
peripatellar region, 3 cm medial to the midpoint of the
medial edge of the patella (1), 2 cm proximal to the su-
perior edge of the patella (2), 3 cm lateral to the mid-
point of the lateral edge of the patella (3) and at the
centre of the patella (4) (Figure 2). Before starting the
measurement, the test is performed once or more on m.
extensor carpi radialis longus to make sure that the
participant has understood the test procedure. A PPT
will be obtained twice from each site and the mean of
the two measurements will be used in the statistical ana-
lysis [54]. The participant will be asked about thelocation and type of their knee pain using the inter-
viewer-administered questionnaire Knee Pain Map,
which has been found reliable for this purpose [55].
The test setup for both isometric muscle strength and
PPTs will be investigated in a test-retest reliability study
on 20 participants.
Other measures
A number of other measures will be obtained in this study
(Table 1). Compliance with exercise will be monitored by
the physiotherapist during the 12 weeks. Compliance is
measured as the total number of exercise sessions com-
pleted out of the expected 24 sessions (two sessions a week
over twelve weeks). Good compliance is defined as partici-
pation in 75 % or more of the exercise sessions, medium
compliance as participation in 50-74 % of the sessions and
poor compliance as participation in less than 50 % of the
sessions. Following the 12-week intervention, the partici-
pants will be requested to record their weekly training to in-
vestigate the long-term compliance. The participants’ use of
medication will be recorded in a medication diary, which
will be examined as part of the follow-up. Compliance with
the other aspects of the MEDIC-treatment will be assessed
Figure 2 PPT measurement sites.
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herence to the treatment (never, every month, every week,
every day, all the time).
At each follow-up, the participants will be asked to
rate their satisfaction with the treatment so far on a five-
point Likert scale.
Adverse and seriously adverse events will be registered
in three ways and divided into index knee or sites otherthan index knee. The project physiotherapist will record
any adverse events that the participant experiences or
tells them about. For the participants allocated to, or
choosing, TKA, a project worker will look through hos-
pital records to register if any pre-defined perioperative
and postoperative adverse events occurred. At all follow-
ups, the assessor will use open-probe questioning to assess
adverse events in all participants (Table 2).
Information on direct health care costs and direct non-
health care costs will be collected retrospectively and at all
follow-ups. Direct health care costs will include costs of all
elements in the perioperative and postoperative period (hos-
pitalisation, surgery, medication, additional health provider
visits, etc.) in participants undergoing a TKA (in both
groups), cost of the MEDIC-treatment and compliance with
the treatment. These aspects will be valued using published
prices for medical costs in Denmark. Direct non-health care
costs will include number of days lost from work, working
shorter hours, sick pay or income (if relevant) and change
in home help.Sample size
Based on the primary outcome KOOS4 at the primary end-
point after 12 months, we expect that the group allocated to
TKA in addition to the MEDIC-treatment will improve at
least 10 points more than the group allocated to MEDIC-
treatment alone. Using a common between-subject standard
deviation of 14 sample size calculations show that 41 parti-
cipants in each group are required to detect a statistical dif-
ference (power of 90 % and significance level at 0.05 (two-
sided)). To account for crossovers and missing data, the
drop-out rate will be set to 20 % and therefore, a total of
100 participants will be randomised.Statistical analysis
The primary outcome measure is KOOS4 12-month follow-
up. Following an intention-to-treat approach, statistical ana-
lysis will be based on a generalized estimating equations
regression model for KOOS4 score at all follow-up times in
order to take into account the repeated measurements on
the patients. The model will incorporate the effects of treat-
ment, follow-up time, treatment-by-follow-up time inter-
action, and KOOS4-score at baseline. Secondary analyses
will assess heterogeneity between sites. Treatment compli-
ance will be correlated to the outcome in order to investi-
gate if compliance is associated with the outcome.Economic evaluation
The economic evaluation will be based on the Danish
healthcare system. It will be conducted as a cost-utility
analysis estimating the ratio between the direct health
and non-health care costs (corrected for cost of funding)
and quality-adjusted life years (QALYs). QALYs will be
Table 2 Adverse events
Method of
registration
Adverse event
Treatment records
All events reported by the participant
Hospital records
During surgery
Patella fracture
Tibia fracture
Femur fracture
Rupture of the patella tendon
Other
Postoperatively
Deep infection
Surgery demanding skin necrosis
Surgery demanding scar tissue adherences
Thrombophlebitis in demand of anticoagulant treatment
Patella sub-/luxation
Supra-condylar femur fracture
Permanent n. peroneus paresis
Pulmonary embolism
Patella fracture
Aseptic loosening
Polyethylene defect (tibia)
Polyethylene defect (patella)
Secondary insertion of patella component
Instability
Pain without loosening
Other events related to the index knee
Other events not related to the index knee
Questionnaire
All events reported by the participant using open-probe questioning
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12-month follow-up.
Timelines
Ethics approval was obtained from The North Denmark Re-
gion in June 2011. Recruitment and training of the involved
project physiotherapist and dietician was undertaken in July
and August 2011 and recruitment of participants started
September 2011. All participants are expected to have com-
pleted the 12-month follow-up by December 2013.
Discussion
There is a lack of high quality evidence concerning the
efficacy of TKA [6] and around 20 % of KOA patients
experience little or no improvement in pain, disability
and quality of life following the TKA [22]. Therefore an
evaluation of the efficacy of TKA compared with other
treatments of KOA is essential.There are several strengths of the design of this study.
Firstly, this will be the first study assessing TKA in the
treatment of KOA in a randomised, controlled design
that can evaluate the additional effect of a TKA to the
recommended non-surgical treatment.
Secondly, the recruitment of participants and multi-
modal approach to the non-surgical treatment resembles
contemporary examination and treatment of KOA in
Denmark and several other countries. Given that the
treatments applied in this study alone are recommended
and, for most of them, well documented in the treatment
of KOA [5,6], we contend that the combination of treat-
ments would be even more efficacious.
Thirdly, the treatment of the participants in this study
following the preliminary assessment will be individua-
lised within the possibilities of a randomised controlled
trial framework. In this way, it will be possible to target
the treatment on the basis of the characteristics of the
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treatment in treatment guidelines [5,7]. The semi-struc-
tured nature of the MEDIC-treatment will enable the
project physiotherapist and dietician to tailor the treat-
ment to the individual within the predefined protocol,
which, on the other hand, will reduce treatment variation
and enhance the reporting of the study and its
replicability.
The multimodal approach in the MEDIC-treatment could
be seen as a limitation since it will be impossible to identify
the efficacy of the different treatments alone. However the
purpose of this study is not to determine the effect of non-
surgical treatments compared with each other, but to evaluate
the additive effect of TKA. For this purpose, the design of the
study can be considered optimal, since the MEDIC-treatment
is a combination of recommended treatment modalities given
to both groups [5,6].
The outcome measures of this study include patient-
reported outcome measures of pain, function, quality of
life, health outcome and self-efficacy. A range of
objective outcome measures are included to incorporate
functional performance, strength, change in weight, and
pressure pain thresholds. The goal of the treatment is to
improve function and quality of life and reduce pain.
The objective outcome measures allow the investigation
of the underlying mechanisms that may explain changes
in pain and function. Furthermore, a health economics
assessment is included to evaluate the treatment in rela-
tion to cost-effectiveness and implementation.
Conclusions
We have designed this study as a randomised controlled
trial to investigate if TKA plus a 12-week multimodal,
optimised non-surgical treatment is more efficacious and
cost-effective than a 12-week multimodal, systematic
non-surgical treatment only in patients with KOA. Since
it is the first study evaluating TKA in a randomised con-
trolled trial, the results will enable evidence-based
recommendations for the treatment of patients with
KOA.
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